NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
NewAmsterdam Pharma Co N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$20.47+0.64 (+3.23%)
Close on Oct 19, 2026
- Market cap
- $2.53B
- P/E (TTM)
- –
- Dividend yield
- –
NewAmsterdam Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Market Cap | $2.45B | $197.05M |
| Enterprise Value | $1.81B | $106.56M |
| PS Ratio | 343.62 | 3.93 |
| PB Ratio | 3.88 | 2.14 |
| P/TBV Ratio | 3.88 | 2.46 |
Enterprise value
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| EV / Sales | 254.61 | 2.69 |
Income (trailing twelve months)
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Revenue | $7.12M | $57.94M |
| Operating Income | -$244.41M | -$21.44M |
| Pretax Income | -$259.50M | -$14.45M |
| Net Income | -$259.50M | -$22.46M |
| EBITDA | -$244.07M | -$16.91M |
| EPS (Diluted) | -$2.15 | -$0.83 |
Margins
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Operating Margin | -3432.2% | -44.5% |
| Pretax Margin | -3644.2% | -13.0% |
| Profit Margin | -3644.2% | -39.2% |
| EBITDA Margin | -3427.5% | -31.3% |
| FCF Margin | -2018.3% | -8.85% |
Returns
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -36.8% | -53.1% |
| Return on Assets (ROA) | -34.2% | -41.0% |
| Return on Invested Capital (ROIC) | -1046.4% | -32.0% |
| Return on Capital Employed (ROCE) | -38.7% | -37.8% |
Growth
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -88.9% | 6.01% |
| Revenue Growth (3Y CAGR) | -39.7% | 2.25% |
Balance sheet
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $633.85M | $62.42M |
| Net Cash (Debt) | $633.85M | $15.68M |
| Net Cash Per Share | $5.30 | $0.65 |
| Equity (Book Value) | $631.42M | $48.79M |
| Book Value Per Share | $5.28 | $1.36 |
| Tangible Book Value | $631.42M | $23.06M |
| Working Capital | $586.23M | $75.77M |
Financial position
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Current Ratio | 9.03 | 3.30 |
| Quick Ratio | 8.69 | 2.39 |
Cash flow (trailing twelve months)
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$143.46M | -$12.35M |
| Capital Expenditures | -$260.00K | -$1.06M |
| Free Cash Flow | -$143.72M | -$20.28M |
| FCF Per Share | -$1.20 | -$0.41 |
Efficiency
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $71.21K | $398.96K |
| Profits Per Employee | -$2.60M | -$732.08K |
| Employee Count | 100 | 73 |
Dividends and yields
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Earnings Yield | -10.6% | -21.2% |
| FCF Yield | -5.87% | -7.64% |
Shares
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 119,537,000 | 59,128,900 |
| Shares Change (YoY) | 12.9% | 11.1% |
| Shares Change (QoQ) | 0.87% | 0.54% |
| Float | 93,061,200 | 48,744,500 |
| Shares Held by Insiders | 22.1% | 11.8% |
Scores
| Measure | NewAmsterdam Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 18.23 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from NewAmsterdam Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.